#AS­CO19: Sanofi sets the stage for a late ar­rival of their mul­ti­ple myelo­ma drug isat­ux­imab — with J&J and Gen­mab lay­ing in wait

4 years ago
R&D

#AS­CO19: Hey Pfiz­er, No­var­tis is go­ing af­ter your block­buster can­cer fran­chise — and they have pos­i­tive OS da­ta

4 years ago
R&D
Pharma

#AS­CO19: Mer­ck’s PD-1 star Keytru­da il­lus­trates just how pow­er­ful it can be over 5 years — with plen­ty of room for im­prove­ment

4 years ago
R&D
Pharma

Turn­ing Point tracks an im­pres­sive ORR rate in NSCLC — but shares skid low­er on sec­ond look

4 years ago
R&D

Io­vance comes back with an­oth­er up­beat can­cer tri­al up­date as #AS­CO19 cur­tain rais­er

4 years ago
R&D

Part­nered with Genen­tech and Mi­crosoft, this biotech be­lieves it can lever­age its knowl­edge of the im­mune sys­tem in­to a $230M-plus IPO

4 years ago
Financing

The com­ing glut? Can­cer cell ther­a­py tri­als are boom­ing as Chi­na ri­vals US on new projects

4 years ago
R&D
China

Af­ter a short stay in the biotech world, Di­et­mar Berg­er is back in Big Phar­ma R&D — and he's tak­ing a promi­nent place in Sanofi

4 years ago
People

New Gilead chief O’Day ax­es world­wide ops chief and re­cruits Bris­tol-My­ers’ Jo­han­na Merci­er for the top team

4 years ago
People
Pharma

As #AS­CO19 looms, a top an­a­lyst show­ers some love — and block­buster sta­tus — on Am­gen's KRAS killer

4 years ago
R&D

IPO boom: An­ti­body ex­perts at Gen­mab out­line glob­al am­bi­tion in pitch for $500M

4 years ago
Financing

Fac­tor VI­II lev­els con­tin­ue to drop in Bio­Marin’s 3-year up­date on he­mo­phil­ia A gene ther­a­py — but wait...

4 years ago
R&D

Brad Lon­car­'s AS­CO19 pre­view: 5 big ideas to watch for at the ul­ti­mate can­cer show of the year

4 years ago
R&D
Biotech Voices

No­var­tis rolls out its next big drug at a record-set­ting price of $2.12M — let the gene ther­a­py pric­ing de­bate be­gin

4 years ago
R&D
Cell/Gene Tx

Pro­ject Snow White: In­ter­nal probe re­veals for­mer MiMedx C-suite spied on em­ploy­ees, lied to reg­u­la­tors and mis­led in­vestors

4 years ago
People
Pharma

Sobered by mount­ing costs, Dy­navax looks to un­load I/O, slash jobs and cir­cle wag­ons around Hep­lisav

4 years ago
People
R&D

No­var­tis chief Vas Narasimhan wants you to know about the '25-plus’ block­busters he has in the pipeline

4 years ago
R&D
Pharma

Ex-FDA com­mish Scott Got­tlieb makes a quick jump back on­to the mon­ey side of biotech

4 years ago
People
Financing

Roche's Chugai to set up new $1B+ lab in Yoko­hama, con­sol­i­dat­ing R&D

4 years ago
R&D
Pharma

Adimab team ac­cus­es promi­nent MIT in­ves­ti­ga­tor Ram Sasisekha­ran of rip­ping off an­ti­bod­ies and pre­sent­ing them as his own

4 years ago
R&D

Be­lea­guered Bio­gen faces the mu­sic as a ris­ing cho­rus of crit­ics push for a trans­for­ma­tive ap­proach to M&A

4 years ago
Deals
Pharma

Mer­ck bets $2.2B on a small can­cer drug biotech, snatch­ing it out of the IPO line­up

4 years ago
Deals
R&D

Can­cer re­search groups urge FDA to over­haul stan­dards for ear­ly cell ther­a­py tri­als, cut­ting time and cost. But will 'pre-com­pet­i­tive' al­liances fly?

4 years ago
R&D
Pharma

Dana-Far­ber’s 4-year le­gal bat­tle shines a light on the ori­gins of PD-1 re­search — forc­ing a reck­on­ing on who pi­o­neered the land­mark can­cer break­through

4 years ago
People
R&D
First page Previous page 191192193194195196197 Next page Last page